Skip to content

Pulmonary Outcomes on Patients With Lung Fibrosis

Pulmonary Outcomes on Patients With Lung Fibrosis

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07088185
Enrollment
60
Registered
2025-07-28
Start date
2024-12-01
Completion date
2026-08-01
Last updated
2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Fibrosis

Keywords

Pulmonary outcomes, Lung fibrosis

Brief summary

The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.

Detailed description

This study will include 60 patients with pulmonary fibrosis from both gender who are aged from 35 - 55 years old.This study will be randomized controlled trial.

Interventions

Routine medical care

OTHERPulmonary rehabilitation

Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* both gender. * patients with cystic fibrosis.

Exclusion criteria

* severe chronic disorders. * heart failure * respiratory failure. * age less than 35 or older than 55 years old.

Design outcomes

Primary

MeasureTime frameDescription
The FEV1 on FVCOne month.The ratio between FEV1 and FVC
FVCOne monthForced vital capacity (FVC).
FEV1One monthForced expiratory volume in the first second (FEV1)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026